{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:42:47Z","timestamp":1790232167664,"version":"4.1.0"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1038\/s41573-020-0065-9","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T06:03:12Z","timestamp":1586325792000},"page":"447-462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Leveraging preclinical models for the development of Alzheimer disease therapeutics"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0568-802X","authenticated-orcid":false,"given":"Kimberly","family":"Scearce-Levie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2620-5165","authenticated-orcid":false,"given":"Pascal E.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3012-7881","authenticated-orcid":false,"given":"Joseph W.","family":"Lewcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"65_CR1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000245","volume":"7","author":"HB van der Worp","year":"2010","unstructured":"van der Worp, H. B. et al. Can animal models of disease reliably inform human studies? PLoS Med. 7, e1000245 (2010).","journal-title":"PLoS Med."},{"key":"65_CR2","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita Jr","year":"2008","unstructured":"DeVita, V. T. Jr & Chu, E. A history of cancer chemotherapy. Cancer Res. 68, 8643\u20138653 (2008).","journal-title":"Cancer Res."},{"key":"65_CR3","unstructured":"Alzheimer\u2019s Disease International. World Alzheimer Report 2018 (Alzheimer\u2019s Disease International, 2018)."},{"key":"65_CR4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.31887\/DCNS.2003.5.1\/hhippius","volume":"5","author":"H Hippius","year":"2003","unstructured":"Hippius, H. & Neundorfer, G. The discovery of Alzheimer\u2019s disease. Dialogues Clin. Neurosci. 5, 101\u2013108 (2003).","journal-title":"Dialogues Clin. Neurosci."},{"key":"65_CR5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol. Med. 8, 595\u2013608 (2016).","journal-title":"EMBO Mol. Med."},{"key":"65_CR6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/jnc.13632","volume":"139","author":"E Karran","year":"2016","unstructured":"Karran, E. & De Strooper, B. The amyloid cascade hypothesis: are we poised for success or failure? J. Neurochem. 139, 237\u2013252 (2016).","journal-title":"J. Neurochem."},{"key":"65_CR7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/gim.2015.117","volume":"18","author":"C Van Cauwenberghe","year":"2016","unstructured":"Van Cauwenberghe, C., Van Broeckhoven, C. & Sleegers, K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet. Med. 18, 421\u2013430 (2016).","journal-title":"Genet. Med."},{"key":"65_CR8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng1934","volume":"39","author":"L Bertram","year":"2007","unstructured":"Bertram, L., McQueen, M. B., Mullin, K., Blacker, D. & Tanzi, R. E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39, 17\u201323 (2007).","journal-title":"Nat. Genet."},{"key":"65_CR9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1083\/jcb.201709069","volume":"217","author":"DV Hansen","year":"2018","unstructured":"Hansen, D. V., Hanson, J. E. & Sheng, M. Microglia in Alzheimer\u2019s disease. J. Cell Biol. 217, 459\u2013472 (2018).","journal-title":"J. Cell Biol."},{"key":"65_CR10","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/ng.3916","volume":"49","author":"R Sims","year":"2017","unstructured":"Sims, R. et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer\u2019s disease. Nat. Genet. 49, 1373\u20131384 (2017). This article describes the identification of coding variants in two additional microglial genes that contribute to AD risk.","journal-title":"Nat. Genet."},{"key":"65_CR11","doi-asserted-by":"crossref","DOI":"10.1002\/cpph.57","volume":"84","author":"K Mullane","year":"2019","unstructured":"Mullane, K. & Williams, M. Preclinical models of Alzheimer\u2019s disease: relevance and translational validity. Curr. Protoc. Pharmacol. 84, e57 (2019).","journal-title":"Curr. Protoc. Pharmacol."},{"key":"65_CR12","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1476-5381.2011.01299.x","volume":"164","author":"D Van Dam","year":"2011","unstructured":"Van Dam, D. & De Deyn, P. P. Animal models in the drug discovery pipeline for Alzheimer\u2019s disease. Br. J. Pharmacol. 164, 1285\u20131300 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"65_CR13","doi-asserted-by":"crossref","first-page":"13287","DOI":"10.1073\/pnas.94.24.13287","volume":"94","author":"C Sturchler-Pierrat","year":"1997","unstructured":"Sturchler-Pierrat, C. et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl Acad. Sci. USA 94, 13287\u201313292 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"65_CR14","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/hmg\/6.9.1535","volume":"6","author":"BT Lamb","year":"1997","unstructured":"Lamb, B. T. et al. Altered metabolism of familial Alzheimer\u2019s disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum. Mol. Genet. 6, 1535\u20131541 (1997).","journal-title":"Hum. Mol. Genet."},{"key":"65_CR15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0896-6273(00)80974-5","volume":"19","author":"DR Borchelt","year":"1997","unstructured":"Borchelt, D. R. et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939\u2013945 (1997).","journal-title":"Neuron"},{"key":"65_CR16","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1074\/jbc.274.10.6483","volume":"274","author":"D Moechars","year":"1999","unstructured":"Moechars, D. et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483\u20136492 (1999).","journal-title":"J. Biol. Chem."},{"key":"65_CR17","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/373523a0","volume":"373","author":"D Games","year":"1995","unstructured":"Games, D. et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523\u2013527 (1995). This is the first study to demonstrate that overexpression of human APP with FAD mutations is sufficient to cause amyloid plaque accumulation in mice.","journal-title":"Nature"},{"key":"65_CR18","doi-asserted-by":"crossref","first-page":"23380","DOI":"10.1074\/jbc.271.38.23380","volume":"271","author":"AG Reaume","year":"1996","unstructured":"Reaume, A. G. et al. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer\u2019s disease mutations and a \u201chumanized\u201d Abeta sequence. J. Biol. Chem. 271, 23380\u201323388 (1996).","journal-title":"J. Biol. Chem."},{"key":"65_CR19","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1523\/JNEUROSCI.20-11-04050.2000","volume":"20","author":"L Mucke","year":"2000","unstructured":"Mucke, L. et al. High-level neuronal expression of abeta 1\u201342 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050\u20134058 (2000).","journal-title":"J. Neurosci."},{"key":"65_CR20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1750-3639.2007.00051.x","volume":"17","author":"J Gotz","year":"2007","unstructured":"Gotz, J. et al. A decade of tau transgenic animal models and beyond. Brain Pathol. 17, 91\u2013103 (2007).","journal-title":"Brain Pathol."},{"key":"65_CR21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.neuron.2010.04.031","volume":"66","author":"KH Ashe","year":"2010","unstructured":"Ashe, K. H. & Zahs, K. R. Probing the biology of Alzheimer\u2019s disease in mice. Neuron 66, 631\u2013645 (2010).","journal-title":"Neuron"},{"key":"65_CR22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/85059","volume":"4","author":"Y Luo","year":"2001","unstructured":"Luo, Y. et al. Mice deficient in BACE1, the Alzheimer\u2019s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 4, 231\u2013232 (2001). This study demonstrates that BACE1 is required for amyloid plaque generation, supporting the rationale to target this protease for treatment of AD.","journal-title":"Nat. Neurosci."},{"key":"65_CR23","doi-asserted-by":"crossref","first-page":"26326","DOI":"10.1074\/jbc.M611687200","volume":"282","author":"L McConlogue","year":"2007","unstructured":"McConlogue, L. et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J. Biol. Chem. 282, 26326\u201326334 (2007).","journal-title":"J. Biol. Chem."},{"key":"65_CR24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nrn.2016.141","volume":"17","author":"JJ Palop","year":"2016","unstructured":"Palop, J. J. & Mucke, L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat. Rev. Neurosci. 17, 777\u2013792 (2016).","journal-title":"Nat. Rev. Neurosci."},{"key":"65_CR25","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1172\/JCI90606","volume":"127","author":"H Sarlus","year":"2017","unstructured":"Sarlus, H. & Heneka, M. T. Microglia in Alzheimer\u2019s disease. J. Clin. Invest. 127, 3240\u20133249 (2017).","journal-title":"J. Clin. Invest."},{"key":"65_CR26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.phrs.2018.03.010","volume":"131","author":"V Shoshan-Barmatz","year":"2018","unstructured":"Shoshan-Barmatz, V., Nahon-Crystal, E., Shteinfer-Kuzmine, A. & Gupta, R. VDAC1, mitochondrial dysfunction, and Alzheimer\u2019s disease. Pharmacol. Res. 131, 87\u2013101 (2018).","journal-title":"Pharmacol. Res."},{"key":"65_CR27","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41577-018-0051-1","volume":"18","author":"Y Shi","year":"2018","unstructured":"Shi, Y. & Holtzman, D. M. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol. 18, 759\u2013772 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"65_CR28","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nature07761","volume":"457","author":"J Lauren","year":"2009","unstructured":"Lauren, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W. & Strittmatter, S. M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128\u20131132 (2009).","journal-title":"Nature"},{"key":"65_CR29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature09635","volume":"469","author":"M Cisse","year":"2011","unstructured":"Cisse, M. et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47\u201352 (2011).","journal-title":"Nature"},{"key":"65_CR30","doi-asserted-by":"publisher","unstructured":"Le Pichon, C. E. et al. Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci. Transl. Med. 9, https:\/\/doi.org\/10.1126\/scitranslmed.aag0394 (2017).","DOI":"10.1126\/scitranslmed.aag0394"},{"key":"65_CR31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0896-6273(03)00124-7","volume":"37","author":"F Kamenetz","year":"2003","unstructured":"Kamenetz, F. et al. APP processing and synaptic function. Neuron 37, 925\u2013937 (2003).","journal-title":"Neuron"},{"key":"65_CR32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s40478-014-0149-z","volume":"2","author":"AA Ittner","year":"2014","unstructured":"Ittner, A. A., Gladbach, A., Bertz, J., Suh, L. S. & Ittner, L. M. p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer\u2019s disease. Acta Neuropathol. Commun. 2, 149 (2014).","journal-title":"Acta Neuropathol. Commun."},{"key":"65_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0110-9","author":"M Temido-Ferreira","year":"2018","unstructured":"Temido-Ferreira, M. et al. Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors. Mol. Psychiatry https:\/\/doi.org\/10.1038\/s41380-018-0110-9 (2018).","journal-title":"Mol. Psychiatry"},{"key":"65_CR34","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1074\/jbc.R115.702704","volume":"291","author":"HH Jarosz-Griffiths","year":"2016","unstructured":"Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V. & Hooper, N. M. Amyloid-beta receptors: the good, the bad, and the prion protein. J. Biol. Chem. 291, 3174\u20133183 (2016).","journal-title":"J. Biol. Chem."},{"key":"65_CR35","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper, B. & Karran, E. The cellular phase of Alzheimer\u2019s disease. Cell 164, 603\u2013615 (2016).","journal-title":"Cell"},{"key":"65_CR36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature 537, 50\u201356 (2016). This article shows that aducanumab treatment was able to reduce plaque load in a small study of patients with AD and supported the progression of the drug to a phase III clinical trial.","journal-title":"Nature"},{"key":"65_CR37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann, B. et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J. Alzheimers Dis. 28, 49\u201369 (2012).","journal-title":"J. Alzheimers Dis."},{"key":"65_CR38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000335913","volume":"10","author":"JL Frost","year":"2012","unstructured":"Frost, J. L. et al. Passive immunization against pyroglutamate-3 amyloid-beta reduces plaque burden in Alzheimer-like transgenic mice: a pilot study. Neurodegener. Dis. 10, 265\u2013270 (2012).","journal-title":"Neurodegener. Dis."},{"key":"65_CR39","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","volume":"43","author":"S Tucker","year":"2015","unstructured":"Tucker, S. et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J. Alzheimers Dis. 43, 575\u2013588 (2015).","journal-title":"J. Alzheimers Dis."},{"key":"65_CR40","first-page":"214","volume":"5","author":"B Vellas","year":"2018","unstructured":"Vellas, B., Aisen, P., Weiner, M. & Touchon, J. What we learn from the CTAD 2018 (Clinical Trials in Alzheimer\u2019s Disease). J. Prev. Alz. Dis. 5, 214\u2013215 (2018).","journal-title":"J. Prev. Alz. Dis."},{"key":"65_CR41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ana.24188","volume":"76","author":"E Karran","year":"2014","unstructured":"Karran, E. & Hardy, J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann. Neurol. 76, 185\u2013205 (2014).","journal-title":"Ann. Neurol."},{"key":"65_CR42","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nbt0812-731","volume":"30","author":"K Garber","year":"2012","unstructured":"Garber, K. Genentech\u2019s Alzheimer\u2019s antibody trial to study disease prevention. Nat. Biotechnol. 30, 731\u2013732 (2012).","journal-title":"Nat. Biotechnol."},{"key":"65_CR43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuron.2011.01.002","volume":"69","author":"TE Golde","year":"2011","unstructured":"Golde, T. E., Schneider, L. S. & Koo, E. H. Anti-abeta therapeutics in Alzheimer\u2019s disease: the need for a paradigm shift. Neuron 69, 203\u2013213 (2011).","journal-title":"Neuron"},{"key":"65_CR44","doi-asserted-by":"crossref","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","volume":"8","author":"ME Kennedy","year":"2016","unstructured":"Kennedy, M. E. et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer\u2019s disease patients. Sci. Transl. Med. 8, 363ra150 (2016). This study is an example of the use of a robust preclinical study design in animal models to inform clinical development with BACE1 inhibitors.","journal-title":"Sci. Transl. Med."},{"key":"65_CR45","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","volume":"378","author":"MF Egan","year":"2018","unstructured":"Egan, M. F. et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease. N. Engl. J. Med. 378, 1691\u20131703 (2018).","journal-title":"N. Engl. J. Med."},{"key":"65_CR46","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1523\/JNEUROSCI.4129-14.2015","volume":"35","author":"PC May","year":"2015","unstructured":"May, P. C. et al. The potent BACE1 inhibitor LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and humans. J. Neurosci. 35, 1199\u20131210 (2015).","journal-title":"J. Neurosci."},{"key":"65_CR47","doi-asserted-by":"crossref","first-page":"11621","DOI":"10.1523\/JNEUROSCI.1405-14.2014","volume":"34","author":"H Jacobsen","year":"2014","unstructured":"Jacobsen, H. et al. Combined treatment with a BACE inhibitor and anti-Abeta antibody gantenerumab enhances amyloid reduction in APPLondon mice. J. Neurosci. 34, 11621\u201311630 (2014).","journal-title":"J. Neurosci."},{"key":"65_CR48","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/med.21622","volume":"40","author":"NM Moussa-Pacha","year":"2020","unstructured":"Moussa-Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H. & Al-Tel, T. H. BACE1 inhibitors: current status and future directions in treating Alzheimer\u2019s disease. Med. Res. Rev. 40, 339\u2013384 (2020).","journal-title":"Med. Res. Rev."},{"key":"65_CR49","doi-asserted-by":"crossref","first-page":"a006304","DOI":"10.1101\/cshperspect.a006304","volume":"2","author":"B De Strooper","year":"2012","unstructured":"De Strooper, B., Iwatsubo, T. & Wolfe, M. S. Presenilins and gamma-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006304 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"65_CR50","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrm1406","volume":"5","author":"R Kopan","year":"2004","unstructured":"Kopan, R. & Ilagan, M. X. Gamma-secretase: proteasome of the membrane? Nat. Rev. Mol. Cell Biol. 5, 499\u2013504 (2004).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"65_CR51","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1471-4159.2001.00012.x","volume":"76","author":"HF Dovey","year":"2001","unstructured":"Dovey, H. F. et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76, 173\u2013181 (2001).","journal-title":"J. Neurochem."},{"key":"65_CR52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/JAD-2011-101065","volume":"25","author":"A Haapasalo","year":"2011","unstructured":"Haapasalo, A. & Kovacs, D. M. The many substrates of presenilin\/gamma-secretase. J. Alzheimers Dis. 25, 3\u201328 (2011).","journal-title":"J. Alzheimers Dis."},{"key":"65_CR53","doi-asserted-by":"publisher","unstructured":"Ou-Yang, M. H. et al. Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice. Sci. Transl. Med. 10, https:\/\/doi.org\/10.1126\/scitranslmed.aao5620 (2018).","DOI":"10.1126\/scitranslmed.aao5620"},{"key":"65_CR54","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.1058189","volume":"293","author":"J Lewis","year":"2001","unstructured":"Lewis, J. et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487\u20131491 (2001). This study demonstrates that overexpression of MAPT containing mutations found in patients with FTD can cause pathology reminiscent of neurofibrillary tangles in patients with AD.","journal-title":"Science"},{"key":"65_CR55","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1601-183X.2007.00372.x","volume":"7","author":"TA Bayer","year":"2008","unstructured":"Bayer, T. A. & Wirths, O. Review on the APP\/PS1KI mouse model: intraneuronal Abeta accumulation triggers axonopathy, neuron loss and working memory impairment. Genes. Brain Behav. 7, 6\u201311 (2008).","journal-title":"Genes. Brain Behav."},{"key":"65_CR56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00429-011-0305-1","volume":"216","author":"MA Lemmens","year":"2011","unstructured":"Lemmens, M. A. et al. Age-related changes of neuron numbers in the frontal cortex of a transgenic mouse model of Alzheimer\u2019s disease. Brain Struct. Funct. 216, 227\u2013237 (2011).","journal-title":"Brain Struct. Funct."},{"key":"65_CR57","volume":"8","author":"AL Wright","year":"2013","unstructured":"Wright, A. L. et al. Neuroinflammation and neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer\u2019s disease. PLoS One 8, e59586 (2013).","journal-title":"PLoS One"},{"key":"65_CR58","doi-asserted-by":"crossref","first-page":"338ra366","DOI":"10.1126\/scitranslmed.aaf2362","volume":"8","author":"MR Brier","year":"2016","unstructured":"Brier, M. R. et al. Tau and Abeta imaging, CSF measures, and cognition in Alzheimer\u2019s disease. Sci. Transl. Med. 8, 338ra366 (2016).","journal-title":"Sci. Transl. Med."},{"key":"65_CR59","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","volume":"60","author":"P Giannakopoulos","year":"2003","unstructured":"Giannakopoulos, P. et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer\u2019s disease. Neurology 60, 1495\u20131500 (2003).","journal-title":"Neurology"},{"key":"65_CR60","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ana.23964","volume":"74","author":"PA Boyle","year":"2013","unstructured":"Boyle, P. A. et al. Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann. Neurol. 74, 478\u2013489 (2013).","journal-title":"Ann. Neurol."},{"key":"65_CR61","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/ana.25380","volume":"85","author":"PA Boyle","year":"2019","unstructured":"Boyle, P. A. et al. Attributable risk of Alzheimer\u2019s dementia attributed to age-related neuropathologies. Ann. Neurol. 85, 114\u2013124 (2019).","journal-title":"Ann. Neurol."},{"key":"65_CR62","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.15252\/embj.201797397","volume":"36","author":"H Sasaguri","year":"2017","unstructured":"Sasaguri, H. et al. APP mouse models for Alzheimer\u2019s disease preclinical studies. EMBO J. 36, 2473\u20132487 (2017).","journal-title":"EMBO J."},{"key":"65_CR63","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nn.3697","volume":"17","author":"T Saito","year":"2014","unstructured":"Saito, T. et al. Single App knock-in mouse models of Alzheimer\u2019s disease. Nat. Neurosci. 17, 661\u2013663 (2014). This study is the first to describe a \u2018knock-in\u2019 APP mouse model of AD that avoids artefacts associated with APP overexpression from a transgene.","journal-title":"Nat. Neurosci."},{"key":"65_CR64","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0059-18.2018","author":"L Chen","year":"2018","unstructured":"Chen, L., Saito, T., Saido, T. C. & Mody, I. Novel quantitative analyses of spontaneous synaptic events in cortical pyramidal cells reveal subtle parvalbumin-expressing interneuron dysfunction in a knock-in mouse model of Alzheimer\u2019s disease. eNeuro https:\/\/doi.org\/10.1523\/ENEURO.0059-18.2018 (2018).","journal-title":"eNeuro"},{"key":"65_CR65","doi-asserted-by":"crossref","DOI":"10.1186\/s12868-018-0446-8","volume":"19","author":"Y Sakakibara","year":"2018","unstructured":"Sakakibara, Y., Sekiya, M., Saito, T., Saido, T. C. & Iijima, K. M. Cognitive and emotional alterations in App knock-in mouse models of Abeta amyloidosis. BMC Neurosci. 19, 46 (2018).","journal-title":"BMC Neurosci."},{"key":"65_CR66","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nbd.2017.10.014","volume":"110","author":"AG Orr","year":"2018","unstructured":"Orr, A. G. et al. Istradefylline reduces memory deficits in aging mice with amyloid pathology. Neurobiol. Dis. 110, 29\u201336 (2018).","journal-title":"Neurobiol. Dis."},{"key":"65_CR67","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neuroscience.2018.02.031","volume":"377","author":"H Izumi","year":"2018","unstructured":"Izumi, H. et al. The disease-modifying drug candidate, SAK3 improves cognitive impairment and inhibits amyloid beta deposition in app knock-in mice. Neuroscience 377, 87\u201397 (2018).","journal-title":"Neuroscience"},{"key":"65_CR68","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.celrep.2019.03.099","volume":"27","author":"C Sala Frigerio","year":"2019","unstructured":"Sala Frigerio, C. et al. The major risk factors for Alzheimer\u2019s disease: age, sex, and genes modulate the microglia response to Abeta plaques. Cell Rep. 27, 1293\u20131306 e1296 (2019).","journal-title":"Cell Rep."},{"key":"65_CR69","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science 261, 921\u2013923 (1993).","journal-title":"Science"},{"key":"65_CR70","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter, W. J. et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 1977\u20131981 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"65_CR71","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 278, 1349\u20131356 (1997).","journal-title":"JAMA"},{"key":"65_CR72","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0694-180","volume":"7","author":"EH Corder","year":"1994","unstructured":"Corder, E. H. et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7, 180\u2013184 (1994).","journal-title":"Nat. Genet."},{"key":"65_CR73","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1523\/JNEUROSCI.0033-12.2012","volume":"32","author":"N Bien-Ly","year":"2012","unstructured":"Bien-Ly, N., Gillespie, A. K., Walker, D., Yoon, S. Y. & Huang, Y. Reducing human apolipoprotein E levels attenuates age-dependent Abeta accumulation in mutant human amyloid precursor protein transgenic mice. J. Neurosci. 32, 4803\u20134811 (2012).","journal-title":"J. Neurosci."},{"key":"65_CR74","doi-asserted-by":"crossref","first-page":"18007","DOI":"10.1523\/JNEUROSCI.3773-11.2011","volume":"31","author":"J Kim","year":"2011","unstructured":"Kim, J. et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J. Neurosci. 31, 18007\u201318012 (2011).","journal-title":"J. Neurosci."},{"key":"65_CR75","first-page":"a006312","volume":"2","author":"DM Holtzman","year":"2012","unstructured":"Holtzman, D. M., Herz, J. & Bu, G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006312 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"65_CR76","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41593-018-0296-9","volume":"22","author":"S Parhizkar","year":"2019","unstructured":"Parhizkar, S. et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat. Neurosci. 22, 191\u2013204 (2019).","journal-title":"Nat. Neurosci."},{"key":"65_CR77","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell 169, 1276\u20131290 e1217 (2017). This study is the first to use single-cell RNA sequencing of microglia in an AD mouse model to identify a Trem2-dependent population of disease-associated microglia.","journal-title":"Cell"},{"key":"65_CR78","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann, S. et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566\u2013581 e569 (2017).","journal-title":"Immunity"},{"key":"65_CR79","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523\u2013527 (2017).","journal-title":"Nature"},{"key":"65_CR80","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1084\/jem.20121274","volume":"209","author":"J Kim","year":"2012","unstructured":"Kim, J. et al. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis. J. Exp. Med. 209, 2149\u20132156 (2012).","journal-title":"J. Exp. Med."},{"key":"65_CR81","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0646-14.2014","volume":"34","author":"F Liao","year":"2014","unstructured":"Liao, F. et al. Anti-ApoE antibody given after plaque onset decreases Abeta accumulation and improves brain function in a mouse model of Abeta amyloidosis. J. Neurosci. 34, 7281\u20137292 (2014).","journal-title":"J. Neurosci."},{"key":"65_CR82","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1172\/JCI96429","volume":"128","author":"F Liao","year":"2018","unstructured":"Liao, F. et al. Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J. Clin. Invest. 128, 2144\u20132155 (2018).","journal-title":"J. Clin. Invest."},{"key":"65_CR83","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","volume":"25","author":"JF Arboleda-Velasquez","year":"2019","unstructured":"Arboleda-Velasquez, J. F. et al. Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: a case report. Nat. Med. 25, 1680\u20131683 (2019).","journal-title":"Nat. Med."},{"key":"65_CR84","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N. Engl. J. Med. 368, 107\u2013116 (2013).","journal-title":"N. Engl. J. Med."},{"key":"65_CR85","doi-asserted-by":"crossref","first-page":"10172","DOI":"10.1073\/pnas.1811411115","volume":"115","author":"FA Sayed","year":"2018","unstructured":"Sayed, F. A. et al. Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy. Proc. Natl Acad. Sci. USA 115, 10172\u201310177 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"65_CR86","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neuron.2016.09.016","volume":"92","author":"P Yuan","year":"2016","unstructured":"Yuan, P. et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 92, 252\u2013264 (2016).","journal-title":"Neuron"},{"key":"65_CR87","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.neuron.2018.01.031","volume":"97","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y. et al. TREM2 is a receptor for beta-amyloid that mediates microglial function. Neuron 97, 1023\u20131031 e1027 (2018).","journal-title":"Neuron"},{"key":"65_CR88","doi-asserted-by":"crossref","first-page":"11524","DOI":"10.1073\/pnas.1710311114","volume":"114","author":"CEG Leyns","year":"2017","unstructured":"Leyns, C. E. G. et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc. Natl Acad. Sci. USA 114, 11524\u201311529 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"65_CR89","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1750-1326-9-20","volume":"9","author":"JD Ulrich","year":"2014","unstructured":"Ulrich, J. D. et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol. Neurodegener. 9, 20 (2014).","journal-title":"Mol. Neurodegener."},{"key":"65_CR90","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer\u2019s disease model. Cell 160, 1061\u20131071 (2015). This study shows that TREM2 could respond to lipid ligands and is required for microglial activation in animal models.","journal-title":"Cell"},{"key":"65_CR91","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","volume":"14","author":"TK Ulland","year":"2018","unstructured":"Ulland, T. K. & Colonna, M. TREM2 - a key player in microglial biology and Alzheimer disease. Nat. Rev. Neurol. 14, 667\u2013675 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"65_CR92","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.20142322","volume":"212","author":"TR Jay","year":"2015","unstructured":"Jay, T. R. et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer\u2019s disease mouse models. J. Exp. Med. 212, 287\u2013295 (2015).","journal-title":"J. Exp. Med."},{"key":"65_CR93","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1523\/JNEUROSCI.2110-16.2016","volume":"37","author":"TR Jay","year":"2017","unstructured":"Jay, T. R. et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer\u2019s disease. J. Neurosci. 37, 637\u2013647 (2017).","journal-title":"J. Neurosci."},{"key":"65_CR94","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41593-019-0433-0","volume":"22","author":"CEG Leyns","year":"2019","unstructured":"Leyns, C. E. G. et al. TREM2 function impedes tau seeding in neuritic plaques. Nat. Neurosci. 22, 1217\u20131222 (2019).","journal-title":"Nat. Neurosci."},{"key":"65_CR95","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13024-018-0262-8","volume":"13","author":"PJ Cheng-Hathaway","year":"2018","unstructured":"Cheng-Hathaway, P. J. et al. The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer\u2019s disease. Mol. Neurodegener. 13, 29 (2018).","journal-title":"Mol. Neurodegener."},{"key":"65_CR96","doi-asserted-by":"crossref","first-page":"12620","DOI":"10.1074\/jbc.RA118.001848","volume":"293","author":"Q Cheng","year":"2018","unstructured":"Cheng, Q. et al. TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer\u2019s disease variant Trem2(R47H) on murine myeloid cell function. J. Biol. Chem. 293, 12620\u201312633 (2018).","journal-title":"J. Biol. Chem."},{"key":"65_CR97","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13024-018-0280-6","volume":"13","author":"X Xiang","year":"2018","unstructured":"Xiang, X. et al. The Trem2 R47H Alzheimer\u2019s risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans. Mol. Neurodegener. 13, 49 (2018).","journal-title":"Mol. Neurodegener."},{"key":"65_CR98","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.neuron.2018.02.002","volume":"97","author":"CYD Lee","year":"2018","unstructured":"Lee, C. Y. D. et al. Elevated TREM2 gene dosage reprograms microglia responsivity and ameliorates pathological phenotypes in Alzheimer\u2019s disease models. Neuron 97, 1032\u20131048 e1035 (2018).","journal-title":"Neuron"},{"key":"65_CR99","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1084\/jem.20171529","volume":"215","author":"WM Song","year":"2018","unstructured":"Song, W. M. et al. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J. Exp. Med. 215, 745\u2013760 (2018).","journal-title":"J. Exp. Med."},{"key":"65_CR100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13024-017-0216-6","volume":"12","author":"SM Bemiller","year":"2017","unstructured":"Bemiller, S. M. et al. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol. Neurodegener. 12, 74 (2017).","journal-title":"Mol. Neurodegener."},{"key":"65_CR101","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911227","author":"K Schlepckow","year":"2020","unstructured":"Schlepckow, K. et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol. Med. https:\/\/doi.org\/10.15252\/emmm.201911227 (2020).","journal-title":"EMBO Mol. Med."},{"key":"65_CR102","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13024-017-0231-7","volume":"12","author":"JL Jankowsky","year":"2017","unstructured":"Jankowsky, J. L. & Zheng, H. Practical considerations for choosing a mouse model of Alzheimer\u2019s disease. Mol. Neurodegener. 12, 89 (2017).","journal-title":"Mol. Neurodegener."},{"key":"65_CR103","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1523\/JNEUROSCI.2642-12.2013","volume":"33","author":"M Iba","year":"2013","unstructured":"Iba, M. et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer\u2019s-like tauopathy. J. Neurosci. 33, 1024\u20131037 (2013).","journal-title":"J. Neurosci."},{"key":"65_CR104","volume":"2","author":"CA Lasagna-Reeves","year":"2012","unstructured":"Lasagna-Reeves, C. A. et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2, 700 (2012).","journal-title":"Sci. Rep."},{"key":"65_CR105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nm.4443","volume":"24","author":"Z He","year":"2018","unstructured":"He, Z. et al. Amyloid-beta plaques enhance Alzheimer\u2019s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med. 24, 29\u201338 (2018).","journal-title":"Nat. Med."},{"key":"65_CR106","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00401-015-1525-x","volume":"131","author":"B Vasconcelos","year":"2016","unstructured":"Vasconcelos, B. et al. Heterotypic seeding of tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of tau-pathology in vivo. Acta Neuropathol. 131, 549\u2013569 (2016).","journal-title":"Acta Neuropathol."},{"key":"65_CR107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresbull.2015.12.003","volume":"122","author":"KD Onos","year":"2016","unstructured":"Onos, K. D., Sukoff Rizzo, S. J., Howell, G. R. & Sasner, M. Toward more predictive genetic mouse models of Alzheimer\u2019s disease. Brain Res. Bull. 122, 1\u201311 (2016).","journal-title":"Brain Res. Bull."},{"key":"65_CR108","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","volume":"9","author":"F Mangialasche","year":"2010","unstructured":"Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P. & Kivipelto, M. Alzheimer\u2019s disease: clinical trials and drug development. Lancet Neurol. 9, 702\u2013716 (2010).","journal-title":"Lancet Neurol."},{"key":"65_CR109","doi-asserted-by":"publisher","unstructured":"Guttinger, S. & Love, A. C. Characterizing scientific failure: putting the replication crisis in context. EMBO Rep, e48765, https:\/\/doi.org\/10.15252\/embr.201948765 (2019).","DOI":"10.15252\/embr.201948765"},{"key":"65_CR110","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrd3439-c1","volume":"10","author":"F Prinz","year":"2011","unstructured":"Prinz, F., Schlange, T. & Asadullah, K. Believe it or not: how much can we rely on published data on potential drug targets? Nat. Rev. Drug Discov. 10, 712 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"65_CR111","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/alzrt90","volume":"3","author":"DW Shineman","year":"2011","unstructured":"Shineman, D. W. et al. Accelerating drug discovery for Alzheimer\u2019s disease: best practices for preclinical animal studies. Alzheimers Res. Ther. 3, 28 (2011).","journal-title":"Alzheimers Res. Ther."},{"key":"65_CR112","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.neuron.2014.10.042","volume":"84","author":"O Steward","year":"2014","unstructured":"Steward, O. & Balice-Gordon, R. Rigor or mortis: best practices for preclinical research in neuroscience. Neuron 84, 572\u2013581 (2014).","journal-title":"Neuron"},{"key":"65_CR113","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature11556","volume":"490","author":"SC Landis","year":"2012","unstructured":"Landis, S. C. et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490, 187\u2013191 (2012).","journal-title":"Nature"},{"key":"65_CR114","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/507423a","volume":"507","author":"S Perrin","year":"2014","unstructured":"Perrin, S. Preclinical research: Make mouse studies work. Nature 507, 423\u2013425 (2014).","journal-title":"Nature"},{"key":"65_CR115","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.neuron.2014.10.007","volume":"84","author":"DE Pankevich","year":"2014","unstructured":"Pankevich, D. E., Altevogt, B. M., Dunlop, J., Gage, F. H. & Hyman, S. E. Improving and accelerating drug development for nervous system disorders. Neuron 84, 546\u2013553 (2014).","journal-title":"Neuron"},{"key":"65_CR116","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/497433a","volume":"497","author":"CG Begley","year":"2013","unstructured":"Begley, C. G. Six red flags for suspect work. Nature 497, 433\u2013434 (2013).","journal-title":"Nature"},{"key":"65_CR117","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrn3475","volume":"14","author":"KS Button","year":"2013","unstructured":"Button, K. S. et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat. Rev. Neurosci. 14, 365\u2013376 (2013). This article highlights how studies that are not properly powered can lead to misleading results and encourage investment in unproven therapeutic strategies.","journal-title":"Nat. Rev. Neurosci."},{"key":"65_CR118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040215","volume":"4","author":"JP Ioannidis","year":"2007","unstructured":"Ioannidis, J. P. Why most published research findings are false: author\u2019s reply to Goodman and Greenland. PLoS Med. 4, e215 (2007).","journal-title":"PLoS Med."},{"key":"65_CR119","doi-asserted-by":"crossref","first-page":"320ps321","DOI":"10.1126\/scitranslmed.aac9888","volume":"8","author":"RJ Kleiman","year":"2016","unstructured":"Kleiman, R. J. & Ehlers, M. D. Data gaps limit the translational potential of preclinical research. Sci. Transl. Med. 8, 320ps321 (2016).","journal-title":"Sci. Transl. Med."},{"key":"65_CR120","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"R Sperling","year":"2014","unstructured":"Sperling, R., Mormino, E. & Johnson, K. The evolution of preclinical Alzheimer\u2019s disease: implications for prevention trials. Neuron 84, 608\u2013622 (2014).","journal-title":"Neuron"},{"key":"65_CR121","volume":"10","author":"S Sankaranarayanan","year":"2015","unstructured":"Sankaranarayanan, S. et al. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One 10, e0125614 (2015).","journal-title":"PLoS One"},{"key":"65_CR122","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13195-018-0341-7","volume":"10","author":"CL Dai","year":"2018","unstructured":"Dai, C. L. et al. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 x Tg-AD mice. Alzheimers Res. Ther. 10, 13 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"65_CR123","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/brain\/awz100","volume":"142","author":"M Albert","year":"2019","unstructured":"Albert, M. et al. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain 142, 1736\u20131750 (2019).","journal-title":"Brain"},{"key":"65_CR124","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.trci.2018.09.005","volume":"4","author":"N Rosenqvist","year":"2018","unstructured":"Rosenqvist, N. et al. Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau. Alzheimers Dement. 4, 521\u2013534 (2018).","journal-title":"Alzheimers Dement."},{"key":"65_CR125","volume":"6","author":"SH Richter","year":"2011","unstructured":"Richter, S. H. et al. Effect of population heterogenization on the reproducibility of mouse behavior: a multi-laboratory study. PLoS One 6, e16461 (2011).","journal-title":"PLoS One"},{"key":"65_CR126","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nmeth.1312","volume":"6","author":"SH Richter","year":"2009","unstructured":"Richter, S. H., Garner, J. P. & Wurbel, H. Environmental standardization: cure or cause of poor reproducibility in animal experiments? Nat. Methods 6, 257\u2013261 (2009).","journal-title":"Nat. Methods"},{"key":"65_CR127","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2003693","volume":"16","author":"B Voelkl","year":"2018","unstructured":"Voelkl, B., Vogt, L., Sena, E. S. & Wurbel, H. Reproducibility of preclinical animal research improves with heterogeneity of study samples. PLoS Biol. 16, e2003693 (2018).","journal-title":"PLoS Biol."},{"key":"65_CR128","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0896-6273(00)80958-7","volume":"19","author":"Mutant mice and neuroscience: recommendations concerning genetic background","year":"1997","unstructured":"Mutant mice and neuroscience: recommendations concerning genetic background. Banbury Conference on genetic background in mice. Neuron 19, 755\u2013759 (1997). This study highlights the challenges of using inbred mouse strains for preclinical research.","journal-title":"Neuron"},{"key":"65_CR129","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0166-2236(96)20021-9","volume":"19","author":"JN Crawley","year":"1996","unstructured":"Crawley, J. N. Unusual behavioral phenotypes of inbred mouse strains. Trends Neurosci. 19, 181\u2013182 (1996).","journal-title":"Trends Neurosci."},{"key":"65_CR130","volume":"15","author":"KD Onos","year":"2019","unstructured":"Onos, K. D. et al. Enhancing face validity of mouse models of Alzheimer\u2019s disease with natural genetic variation. PLoS Genet. 15, e1008155 (2019).","journal-title":"PLoS Genet."},{"key":"65_CR131","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10428-1","volume":"10","author":"J Gamache","year":"2019","unstructured":"Gamache, J. et al. Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice. Nat. Commun. 10, 2479 (2019).","journal-title":"Nat. Commun."},{"key":"65_CR132","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neuroscience.2011.06.006","volume":"190","author":"M Nikodemova","year":"2011","unstructured":"Nikodemova, M. & Watters, J. J. Outbred ICR\/CD1 mice display more severe neuroinflammation mediated by microglial TLR4\/CD14 activation than inbred C57Bl\/6 mice. Neuroscience 190, 67\u201374 (2011).","journal-title":"Neuroscience"},{"key":"65_CR133","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00335-015-9595-6","volume":"26","author":"MA Bogue","year":"2015","unstructured":"Bogue, M. A., Churchill, G. A. & Chesler, E. J. Collaborative cross and diversity outbred data resources in the mouse phenome database. Mamm. Genome 26, 511\u2013520 (2015).","journal-title":"Mamm. Genome"},{"key":"65_CR134","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1534\/genetics.116.198838","volume":"206","author":"A Srivastava","year":"2017","unstructured":"Srivastava, A. et al. Genomes of the mouse collaborative cross. Genetics 206, 537\u2013556 (2017).","journal-title":"Genetics"},{"key":"65_CR135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.15252\/embr.201643717","volume":"18","author":"ET Liu","year":"2017","unstructured":"Liu, E. T. et al. Of mice and CRISPR: the post-CRISPR future of the mouse as a model system for the human condition. EMBO Rep. 18, 187\u2013193 (2017).","journal-title":"EMBO Rep."},{"key":"65_CR136","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley, H. et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129\u201310140 (2006).","journal-title":"J. Neurosci."},{"key":"65_CR137","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41593-018-0145-x","volume":"21","author":"A Deczkowska","year":"2018","unstructured":"Deczkowska, A., Amit, I. & Schwartz, M. Microglial immune checkpoint mechanisms. Nat. Neurosci. 21, 779\u2013786 (2018).","journal-title":"Nat. Neurosci."},{"key":"65_CR138","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tins.2006.07.001","volume":"29","author":"WJ Streit","year":"2006","unstructured":"Streit, W. J. Microglial senescence: does the brain\u2019s immune system have an expiration date? Trends Neurosci. 29, 506\u2013510 (2006).","journal-title":"Trends Neurosci."},{"key":"65_CR139","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.celrep.2017.09.039","volume":"21","author":"H Mathys","year":"2017","unstructured":"Mathys, H. et al. Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. Cell Rep. 21, 366\u2013380 (2017). This study is the first to use single-cell RNA sequencing in brains of patients with AD to better understand how disease alters cellular state.","journal-title":"Cell Rep."},{"key":"65_CR140","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11295","volume":"7","author":"K Srinivasan","year":"2016","unstructured":"Srinivasan, K. et al. Untangling the brain\u2019s neuroinflammatory and neurodegenerative transcriptional responses. Nat. Commun. 7, 11295 (2016).","journal-title":"Nat. Commun."},{"key":"65_CR141","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.celrep.2017.12.066","volume":"22","author":"BA Friedman","year":"2018","unstructured":"Friedman, B. A. et al. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer\u2019s disease not evident in mouse models. Cell Rep. 22, 832\u2013847 (2018).","journal-title":"Cell Rep."},{"key":"65_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.12.007","author":"AA Nugent","year":"2020","unstructured":"Nugent, A. A. et al. TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron https:\/\/doi.org\/10.1016\/j.neuron.2019.12.007 (2020).","journal-title":"Neuron"},{"key":"65_CR143","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41586-019-1195-2","volume":"570","author":"H Mathys","year":"2019","unstructured":"Mathys, H. et al. Single-cell transcriptomic analysis of Alzheimer\u2019s disease. Nature 570, 332\u2013337 (2019).","journal-title":"Nature"},{"key":"65_CR144","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature10821","volume":"482","author":"MA Israel","year":"2012","unstructured":"Israel, M. A. et al. Probing sporadic and familial Alzheimer\u2019s disease using induced pluripotent stem cells. Nature 482, 216\u2013220 (2012).","journal-title":"Nature"},{"key":"65_CR145","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13195-017-0268-4","volume":"9","author":"C Arber","year":"2017","unstructured":"Arber, C., Lovejoy, C. & Wray, S. Stem cell models of Alzheimer\u2019s disease: progress and challenges. Alzheimers Res. Ther. 9, 42 (2017).","journal-title":"Alzheimers Res. Ther."},{"key":"65_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.07.010","author":"D Kwart","year":"2019","unstructured":"Kwart, D. et al. A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP beta-CTFs, not Abeta. Neuron https:\/\/doi.org\/10.1016\/j.neuron.2019.07.010 (2019).","journal-title":"Neuron"},{"key":"65_CR147","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nature13800","volume":"515","author":"SH Choi","year":"2014","unstructured":"Choi, S. H. et al. A three-dimensional human neural cell culture model of Alzheimer\u2019s disease. Nature 515, 274\u2013278 (2014).","journal-title":"Nature"},{"key":"65_CR148","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41593-018-0175-4","volume":"21","author":"J Park","year":"2018","unstructured":"Park, J. et al. A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer\u2019s disease. Nat. Neurosci. 21, 941\u2013951 (2018).","journal-title":"Nat. Neurosci."},{"key":"65_CR149","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1194637","volume":"330","author":"F Ginhoux","year":"2010","unstructured":"Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841\u2013845 (2010).","journal-title":"Science"},{"key":"65_CR150","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/nm.4189","volume":"22","author":"J Muffat","year":"2016","unstructured":"Muffat, J. et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat. Med. 22, 1358\u20131367 (2016).","journal-title":"Nat. Med."},{"key":"65_CR151","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.neuron.2017.03.042","volume":"94","author":"EM Abud","year":"2017","unstructured":"Abud, E. M. et al. iPSC-derived human microglia-like cells to study neurological diseases. Neuron 94, 278\u2013293 e279 (2017).","journal-title":"Neuron"},{"key":"65_CR152","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.stemcr.2017.05.017","volume":"8","author":"W Haenseler","year":"2017","unstructured":"Haenseler, W. et al. A highly efficient human pluripotent stem cell microglia model displays a neuronal-co-culture-specific expression profile and inflammatory response. Stem Cell Rep. 8, 1727\u20131742 (2017).","journal-title":"Stem Cell Rep."},{"key":"65_CR153","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nn.4534","volume":"20","author":"H Pandya","year":"2017","unstructured":"Pandya, H. et al. Differentiation of human and murine induced pluripotent stem cells to microglia-like cells. Nat. Neurosci. 20, 753\u2013759 (2017).","journal-title":"Nat. Neurosci."},{"key":"65_CR154","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1073\/pnas.1222878110","volume":"110","author":"J Seok","year":"2013","unstructured":"Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110, 3507\u20133512 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"65_CR155","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.cell.2019.11.010","volume":"179","author":"L Geirsdottir","year":"2019","unstructured":"Geirsdottir, L. et al. Cross-species single-cell analysis reveals divergence of the primate microglia program. Cell 179, 1609\u20131622 e1616 (2019).","journal-title":"Cell"},{"key":"65_CR156","doi-asserted-by":"publisher","unstructured":"Gosselin, D. et al. An environment-dependent transcriptional network specifies human microglia identity. Science 356, https:\/\/doi.org\/10.1126\/science.aal3222 (2017). This study highlights the challenge of using cultured microglia to predict in vivo phenotypes, as the culturing process alone led to significant gene expression changes.","DOI":"10.1126\/science.aal3222"},{"key":"65_CR157","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.neuron.2017.04.043","volume":"94","author":"CJ Bohlen","year":"2017","unstructured":"Bohlen, C. J. et al. Diverse requirements for microglial survival, specification, and function revealed by defined-medium cultures. Neuron 94, 759\u2013773 e758 (2017).","journal-title":"Neuron"},{"key":"65_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.07.002","author":"J Hasselmann","year":"2019","unstructured":"Hasselmann, J. et al. Development of a chimeric model to study and manipulate human microglia in vivo. Neuron https:\/\/doi.org\/10.1016\/j.neuron.2019.07.002 (2019).","journal-title":"Neuron"},{"key":"65_CR159","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/nyas.12417","volume":"1313","author":"TJ Scott","year":"2014","unstructured":"Scott, T. J., O\u2019Connor, A. C., Link, A. N. & Beaulieu, T. J. Economic analysis of opportunities to accelerate Alzheimer\u2019s disease research and development. Ann. N. Y. Acad. Sci. 1313, 17\u201334 (2014).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"65_CR160","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","volume":"335","author":"PE Cramer","year":"2012","unstructured":"Cramer, P. E. et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335, 1503\u20131506 (2012). This study reports impressive efficacy of bexarotene treatment in AD mouse models although not all of the effects observed were reproducible in other laboratories.","journal-title":"Science"},{"key":"65_CR161","doi-asserted-by":"crossref","first-page":"924-f","DOI":"10.1126\/science.1235505","volume":"340","author":"K Veeraraghavalu","year":"2013","unstructured":"Veeraraghavalu, K. et al. Comment on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d. Science 340, 924-f (2013).","journal-title":"Science"},{"key":"65_CR162","doi-asserted-by":"crossref","first-page":"924-d","DOI":"10.1126\/science.1234089","volume":"340","author":"AR Price","year":"2013","unstructured":"Price, A. R. et al. Comment on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d. Science 340, 924-d (2013).","journal-title":"Science"},{"key":"65_CR163","doi-asserted-by":"crossref","first-page":"924-e","DOI":"10.1126\/science.1233937","volume":"340","author":"I Tesseur","year":"2013","unstructured":"Tesseur, I. et al. Comment on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d. Science 340, 924-e (2013).","journal-title":"Science"},{"key":"65_CR164","doi-asserted-by":"crossref","first-page":"924-c","DOI":"10.1126\/science.1235809","volume":"340","author":"NF Fitz","year":"2013","unstructured":"Fitz, N. F., Cronican, A. A., Lefterov, I. & Koldamova, R. Comment on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d. Science 340, 924-c (2013).","journal-title":"Science"},{"key":"65_CR165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1326-8-18","volume":"8","author":"KD LaClair","year":"2013","unstructured":"LaClair, K. D. et al. Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP\/PS1 mice. Mol. Neurodegener. 8, 18 (2013).","journal-title":"Mol. Neurodegener."},{"key":"65_CR166","doi-asserted-by":"crossref","first-page":"924-g","DOI":"10.1126\/science.1234114","volume":"340","author":"GE Landreth","year":"2013","unstructured":"Landreth, G. E. et al. Response to comments on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d. Science 340, 924-g (2013).","journal-title":"Science"},{"key":"65_CR167","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.neurobiolaging.2014.03.029","volume":"35","author":"V Bomben","year":"2014","unstructured":"Bomben, V. et al. Bexarotene reduces network excitability in models of Alzheimer\u2019s disease and epilepsy. Neurobiol. Aging 35, 2091\u20132095 (2014).","journal-title":"Neurobiol. Aging"},{"key":"65_CR168","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1523\/JNEUROSCI.5198-13.2014","volume":"34","author":"A Boehm-Cagan","year":"2014","unstructured":"Boehm-Cagan, A. & Michaelson, D. M. Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene. J. Neurosci. 34, 7293\u20137301 (2014).","journal-title":"J. Neurosci."},{"key":"65_CR169","doi-asserted-by":"crossref","first-page":"30538","DOI":"10.1074\/jbc.M114.600833","volume":"289","author":"LM Tai","year":"2014","unstructured":"Tai, L. M. et al. Amyloid-beta pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. J. Biol. Chem. 289, 30538\u201330555 (2014).","journal-title":"J. Biol. Chem."},{"key":"65_CR170","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2015.04.020","volume":"100","author":"E O\u2019Hare","year":"2016","unstructured":"O\u2019Hare, E. et al. Lack of support for bexarotene as a treatment for Alzheimer\u2019s disease. Neuropharmacology 100, 124\u2013130 (2016).","journal-title":"Neuropharmacology"},{"key":"65_CR171","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.trci.2016.06.001","volume":"2","author":"K Ghosal","year":"2016","unstructured":"Ghosal, K. et al. A randomized controlled study to evaluate the effect of bexarotene on amyloid-beta and apolipoprotein E metabolism in healthy subjects. Alzheimers Dement. 2, 110\u2013120 (2016).","journal-title":"Alzheimers Dement."},{"key":"65_CR172","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-016-0173-2","volume":"8","author":"JL Cummings","year":"2016","unstructured":"Cummings, J. L. et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer\u2019s disease. Alzheimers Res. Ther. 8, 4 (2016).","journal-title":"Alzheimers Res. Ther."},{"key":"65_CR173","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3233\/JAD-150405","volume":"49","author":"N Pierrot","year":"2016","unstructured":"Pierrot, N. et al. Targretin improves cognitive and biological markers in a patient with Alzheimer\u2019s disease. J. Alzheimers Dis. 49, 271\u2013276 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"65_CR174","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrg3899","volume":"16","author":"O Shalem","year":"2015","unstructured":"Shalem, O., Sanjana, N. E. & Zhang, F. High-throughput functional genomics using CRISPR-Cas9. Nat. Rev. Genet. 16, 299\u2013311 (2015).","journal-title":"Nat. Rev. Genet."},{"key":"65_CR175","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cell.2013.04.025","volume":"153","author":"H Wang","year":"2013","unstructured":"Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR\/Cas-mediated genome engineering. Cell 153, 910\u2013918 (2013).","journal-title":"Cell"},{"key":"65_CR176","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nbt.2661","volume":"31","author":"D Li","year":"2013","unstructured":"Li, D. et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat. Biotechnol. 31, 681\u2013683 (2013).","journal-title":"Nat. Biotechnol."},{"key":"65_CR177","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/cr.2014.11","volume":"24","author":"T Hai","year":"2014","unstructured":"Hai, T., Teng, F., Guo, R., Li, W. & Zhou, Q. One-step generation of knockout pigs by zygote injection of CRISPR\/Cas system. Cell Res. 24, 372\u2013375 (2014).","journal-title":"Cell Res."},{"key":"65_CR178","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/jmcb\/mjv061","volume":"7","author":"Q Zou","year":"2015","unstructured":"Zou, Q. et al. Generation of gene-target dogs using CRISPR\/Cas9 system. J. Mol. Cell Biol. 7, 580\u2013583 (2015).","journal-title":"J. Mol. Cell Biol."},{"key":"65_CR179","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075091","volume":"8","author":"J Gaiottino","year":"2013","unstructured":"Gaiottino, J. et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 8, e75091 (2013).","journal-title":"PLoS One"},{"key":"65_CR180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","volume":"91","author":"M Bacioglu","year":"2016","unstructured":"Bacioglu, M. et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91, 56\u201366 (2016). This article highlights the utility of neurofilament light chain as a biomarker in AD and other neurodegenerative diseases.","journal-title":"Neuron"},{"key":"65_CR181","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ana.24052","volume":"75","author":"CS Scherling","year":"2014","unstructured":"Scherling, C. S. et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann. Neurol. 75, 116\u2013126 (2014).","journal-title":"Ann. Neurol."},{"key":"65_CR182","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg, H. et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 73, 60\u201367 (2016).","journal-title":"JAMA Neurol."},{"key":"65_CR183","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K. & Alzheimer\u2019s Disease Neuroimaging, I. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 74, 557\u2013566 (2017).","journal-title":"JAMA Neurol."},{"key":"65_CR184","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.0000000000001491","volume":"84","author":"J Kuhle","year":"2015","unstructured":"Kuhle, J. et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 84, 1639\u20131643 (2015).","journal-title":"Neurology"},{"key":"65_CR185","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle, J. et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92, e1007\u2013e1015 (2019).","journal-title":"Neurology"},{"key":"65_CR186","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","volume":"266","author":"B Olsson","year":"2019","unstructured":"Olsson, B. et al. NFL is a marker of treatment response in children with SMA treated with nusinersen. J. Neurol. 266, 2129\u20132136 (2019).","journal-title":"J. Neurol."},{"key":"65_CR187","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.neuroscience.2017.04.030","volume":"354","author":"A Clement","year":"2017","unstructured":"Clement, A., Mitchelmore, C., Andersson, D. R. & Asuni, A. A. Cerebrospinal fluid neurofilament light chain as a biomarker of neurodegeneration in the Tg4510 and MitoPark mouse models. Neuroscience 354, 101\u2013109 (2017).","journal-title":"Neuroscience"},{"key":"65_CR188","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","volume":"2","author":"J Ferrero","year":"2016","unstructured":"Ferrero, J. et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease. Alzheimers Dement. 2, 169\u2013176 (2016).","journal-title":"Alzheimers Dement."},{"key":"65_CR189","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archneur.65.8.1031","volume":"65","author":"AS Fleisher","year":"2008","unstructured":"Fleisher, A. S. et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65, 1031\u20131038 (2008).","journal-title":"Arch. Neurol."},{"key":"65_CR190","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody, R. S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N. Engl. J. Med. 369, 341\u2013350 (2013).","journal-title":"N. Engl. J. Med."},{"key":"65_CR191","doi-asserted-by":"crossref","first-page":"870","DOI":"10.2353\/ajpath.2010.090452","volume":"176","author":"H Martinez-Coria","year":"2010","unstructured":"Martinez-Coria, H. et al. Memantine improves cognition and reduces Alzheimer\u2019s-like neuropathology in transgenic mice. Am. J. Pathol. 176, 870\u2013880 (2010).","journal-title":"Am. J. Pathol."},{"key":"65_CR192","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1124\/jpet.104.071027","volume":"311","author":"R Minkeviciene","year":"2004","unstructured":"Minkeviciene, R., Banerjee, P. & Tanila, H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer\u2019s disease. J. Pharmacol. Exp. Ther. 311, 677\u2013682 (2004).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"65_CR193","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejphar.2012.12.023","volume":"703","author":"A Nagakura","year":"2013","unstructured":"Nagakura, A., Shitaka, Y., Yarimizu, J. & Matsuoka, N. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer\u2019s disease and effects of donepezil and memantine. Eur. J. Pharmacol. 703, 53\u201361 (2013).","journal-title":"Eur. J. Pharmacol."},{"key":"65_CR194","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0","volume":"14","author":"B Winblad","year":"1999","unstructured":"Winblad, B. & Poritis, N. Memantine in severe dementia: results of the 9M-best study (benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Psychiatry 14, 135\u2013146 (1999).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"65_CR195","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg, B. et al. Memantine in moderate-to-severe Alzheimer\u2019s disease. N. Engl. J. Med. 348, 1333\u20131341 (2003).","journal-title":"N. Engl. J. Med."},{"key":"65_CR196","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/gps.1949","volume":"23","author":"S Gauthier","year":"2008","unstructured":"Gauthier, S., Loft, H. & Cummings, J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer\u2019s disease by memantine: a pooled data analysis. Int. J. Geriatr. Psychiatry 23, 537\u2013545 (2008).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"65_CR197","doi-asserted-by":"crossref","first-page":"eaal2029","DOI":"10.1126\/scitranslmed.aal2029","volume":"9","author":"K Yanamandra","year":"2017","unstructured":"Yanamandra, K. et al. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Sci Transl Med 9, eaal2029 (2017).","journal-title":"Sci Transl Med"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41573-020-0065-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41573-020-0065-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41573-020-0065-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:45:10Z","timestamp":1684604710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-020-0065-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":197,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["65"],"URL":"https:\/\/doi.org\/10.1038\/s41573-020-0065-9","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,8]]},"assertion":[{"value":"26 February 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employees and shareholders of Denali Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}